Overview

First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy

Status:
Recruiting
Trial end date:
2022-06-15
Target enrollment:
Participant gender:
Summary
A phase 1, randomized, placebo-controlled, double-blind, dose escalation trial combining single-ascending dose and multiple-ascending dose phases of NI006 or placebo, followed by an open-label extension phase in subjects with Amyloid Transthyretin Cardiomyopathy (ATTR-CM).
Phase:
Phase 1
Details
Lead Sponsor:
Neurimmune AG